
    
      The proposed study is a double blind, placebo controlled, parallel designed investigation
      comparing the effect of one of four atypical antipsychotics (aripiprazole, olanzapine,
      quetiapine, and/or risperidone), treatment alone to treatment with one of these in addition
      to treatment with guanfacine to maximum dose of 3.0 mg per day on a cognitive task
      performance in schizophrenic patients. The study will take place over fourteen weeks.
      Patients will receive study medication for the last ten weeks of the protocol.
    
  